Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.46 |
| ▸ | TPH1 | P17752 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | BLVRB | P30043 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403519 | 0.85 | MAOA (0.51) | NPC1RAB9ASMN1; SMN2TP53MAOA | |
| SCHEMBL18950875 | 0.82 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2TP53ATM | |
| SCHEMBL18950847 | 0.79 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2TP53TPH1 | |
| SCHEMBL60333 | 0.78 | MAOA (0.68) | NPC1RAB9ASMN1; SMN2TP53PSMD11 | |
| SCHEMBL24505301 | 0.77 | S1PR1 (0.60) | NPC1RAB9ASMN1; SMN2TP53NR1H4 | |
| SCHEMBL28593073 | 0.77 | NR1H4 (0.78) | NPC1RAB9ASMN1; SMN2TP53ATM | |
| SCHEMBL3059321 | 0.77 | NR1H4 (0.78) | NPC1RAB9ASMN1; SMN2TP53ATM | |
| SCHEMBL18950861 | 0.74 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2TP53MAOA | |
| SCHEMBL61059 | 0.74 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2TP53PSMD11 | |
| SCHEMBL20247350 | 0.73 | L3MBTL1 (0.44) | HDAC6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3889142-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3632902-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3549936-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3549936-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345895-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3103800-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3178816-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-7772259-B2 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772259-B2 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7419991-B2 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419991-B2 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7304080-B2 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304080-B2 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | UPF1, RIOX2, RNMT | NPC1 1403/4885RAB9A 4299/4885SMN1; SMN2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.